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Knowledge of both the global chromatin structure
and the gene expression programs of human embry-
onic stem cells (ESCs) and induced pluripotent stem
cells (iPSCs) should provide a robust means to
assess whether the genomes of these cells have
similar pluripotent states. Recent studies have sug-
gested that ESCs and iPSCs represent different
pluripotent states with substantially different gene
expression profiles. We describe here a comparison
of global chromatin structure and gene expression
data for a panel of human ESCs and iPSCs.
Genome-wide maps of nucleosomes with histone
H3K4me3 and H3K27me3 modifications indicate
that there is little difference between ESCs and iPSCs
with respect to these marks. Gene expression
profiles confirm that the transcriptional programs of
ESCs and iPSCs show very few consistent differ-
ences. Although some variation in chromatin struc-
ture and gene expression was observed in these
cell lines, these variations did not serve to distinguish
ESCs from iPSCs.
INTRODUCTION
Mammalian cells can be directly reprogrammed into induced
pluripotent stem cells (iPSCs) by introduction of defined sets of
transcriptional regulators (Takahashi and Yamanaka, 2006;
Maherali et al., 2007; Nakagawa et al., 2008; Okita et al., 2007;
Takahashi et al., 2007; Wernig et al., 2007; Yu et al., 2007; Aoi
et al., 2008). These iPSCs hold great potential for regenerative
medicine because they are similar to pluripotent embryonic
stem cells (ESCs) and can be derived in a patient-specific
manner from adult somatic cells (Yamanaka, 2007; Saha and
Jaenisch, 2009). ESCs and iPSCs are highly similar in a broad
range of phenotypic behaviors, including cell morphology,
expression of pluripotency markers, teratoma formation, ability
to differentiate into germ layers, and tetraploid complementation
(Okita et al., 2007; Wernig et al., 2007; Boland et al., 2009; Kanget al., 2009; Smith et al., 2009; Zhao et al., 2009). However,
recent studies comparing the gene expression profiles of ESCs
and iPSCs have suggested that iPSCs are a unique cellular
subtype distinct from ESCs (Chin et al., 2009; Marchetto et al.,
2009) and that iPSCs retain some of the expression program of
their cell of origin (Ghosh et al., 2010). It is important to under-
stand whether there are genuine differences in the global chro-
matin structure and the gene expression programs of human
ESCs and iPSCs, given that such differences may impact the
potential therapeutic use of iPSCs.
Trithorax group (TrxG) and Polycomb group (PcG) protein
complexes are key regulators of chromatin structures that are
required for segmental identity in the developing embryo and
contribute tomaintenance of the pluripotent ESC state (Ringrose
and Paro, 2004; Schuettengruber et al., 2007; Pietersen and van
Lohuizen, 2008). TrxG complexes catalyze histone H3 lysine 4
trimethylation (H23K4me3) at promoters of protein-coding
genes (Bernstein et al., 2002; Santos-Rosa et al., 2002; Ng
et al., 2003; Schneider et al., 2004; Guenther et al., 2007; Mikkel-
sen et al., 2007), miRNA loci (Marson et al., 2008; Ozsolak et al.,
2008), and noncoding lincRNA loci (Guttman et al., 2009). The
PcG protein complex PRC2 catalyzes histone H3 lysine 27 trime-
thylation (H3K27me3), which contributes to repression of devel-
opmental genes (Schuettengruber et al., 2007; Schwartz and
Pirrotta, 2008; Simon and Kingston, 2009). Histone H3K4me3
and H3K27me3 histone modifications are generally associated
with transcriptionally active and repressed domains of the
genome, respectively, although both modifications can occur
at silent genes encoding developmental regulators that are
poised for future activation (Bernstein et al., 2006; Lee et al.,
2006; Guenther et al., 2007). Genome-wide maps of these
histone modifications, which produce robust signals in ChIP-
Seq experiments, can be especially useful for comparing tran-
scriptional and developmental states of cells, particularly when
coupled with gene expression profiling.
Microarray-based gene expression profiling has proven to be
a powerful approach to characterize the transcriptional state of
cells and to identify differences between cells of different types
or states (Ebert and Golub, 2004; Ivanova et al., 2006).
Comparing the gene expression profiles of ESCs and iPSCs
could permit identification of any unique and consistent differ-
ences between these two cell types. However, comparative
analysis of expression data can be challenging because ofCell Stem Cell 7, 249–257, August 6, 2010 ª2010 Elsevier Inc. 249
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reagents, and analytical techniques. In comparing the expres-
sion profiles of ESCs and iPSCs, it is therefore important to
use analytical methods that account for the noise in the data
and require reproducible results across multiple experiments
(Bammler et al., 2005).
We have investigated whether a panel of human ESCs differs
consistently from a panel of human iPSCs using both genome-
wide maps of histone H3K4me3 and H3K27me3 modifications
and gene expression analysis. We have also reanalyzed a large
collection of previously published gene expression data by using
different analysis methods. Our results reveal that small varia-
tions in the chromatin structure or gene expression occur among
different ESC and iPSC lines, but we do not observe a consistent
signature that distinguishes iPSC lines from ESC lines when
examined after extended culture.
RESULTS AND DISCUSSION
Genome-wide Maps of Chromatin Modifications Show
that Human iPSCs Share Key Features with ESCs
WeusedChIP-Seq tomapH3K4me3andH3K27me3occupancy
genome-wide in six independent ESC lines and six independent
iPSC lines grown under identical conditions (Figure 1). The ESCs
included two male lines (BG01 and WIBR1) and four female
lines (BG03, WIBR2, WIBR3, and WIBR7), each derived from
a different donor (Lengner et al., 2010). The iPSC lines were
generated from human fibroblasts with a doxycycline-inducible
reprogramming system with OCT4, SOX2, and KLF4 genes
(Hockemeyer et al., 2008; Soldner et al., 2009). Four of the iPSCs
were derived from a female donor (iPS A1, iPS C1, iPS4, and iPS
A6; described and characterized in Hockemeyer et al., 2008) and
two from a male donor (iPS PDB2lox-17 and iPS PDB2lox-21;
describedandcharacterized inSoldner et al., 2009). All iPSC lines
contained integrated transgenes, but were doxycycline indepen-
dent for growth, indicating that transgene expression was not
required for propagation of these pluripotent cells.
The maps of histone H3K4me3 and H3K27me3 were highly
similar at protein-coding and noncoding genes in all 12 ESC
and iPSC lines when examined by enrichment profiles (Figures
1A and 1C), heat maps (Figures 1B and 1D), or inspection of
gene tracks (Figures 1E and 1F). Nucleosomes with H3K4me3
occurred at the vast majority of protein-coding genes in both
ESCs and iPSCs (85%), with maximal enrichment occurringFigure 1. Genome-wide Maps of Chromatin Modifications Show Huma
(A) Composite H3K4me3 enrichment profile for all RefSeq genes in ESCs (solid b
transcription of the average gene is noted by an arrow.
(B) ChIP-Seq density heat map of histone H3K4me3 (blue) for all RefSeq genes. G
arranged from highest to lowest density. The TSS and direction of transcription o
relative to the TSS shown.
(C) Composite H3K27me3 enrichment profile for all RefSeq genes enriched for H3
of transcription of the average gene is noted by an arrow.
(D) ChIP-Seq density heat map of histone H3K27me3 (green) for all RefSeq genes.
arranged from highest to lowest density. The TSS and direction of transcription o
relative to the TSS shown.
(E) ChIP-Seq density for H3K4me3 (blue) at the OCT4 locus in human ESC, iPSC
scale is shown above the gene tracks.
(F) ChIP-Seq density for H3K27me3 (green) in the HOXA cluster in human ESC, iPS
the scale is shown above the gene tracks. See also Tables S1–S4.200 bp downstream of transcriptional start sites (Figures 1A,
1B, and 1E; Table S1 available online). H3K4me3-modified
nucleosomes also occupied the start sites of known and pre-
dicted noncoding RNAs in both cell types, which include ESC-
specific RNAs associated with pluripotency (Marson et al.,
2008) (Table S1). H3K27me3-modified nucleosomes occurred
primarily in the promoters of 2000 repressed genes, many of
which encode key regulators of development (Figures 1C, 1D,
and 1F; Table S1). H3K27me3 marked small domains (1–5 kb)
within certain gene promoter regions and large domains extend-
ing across >100 kb of the HOX gene clusters. These results indi-
cate that the genomes of human iPSCs possess the general
features of Trx- and PcG-mediated histone modifications previ-
ously described in ESCs (Bernstein et al., 2006; Boyer et al.,
2006; Bracken et al., 2006; Lee et al., 2006; Guenther et al.,
2007; Pan et al., 2007; Zhao et al., 2007; Mikkelsen et al., 2008).
Similarity in Genes and Regions Occupied by Modified
Histones in ESCs and iPSCs
Inspection of gene tracks revealed some variation in H3K4me3
andH3K27me3 nucleosome occupancy among these cells lines,
prompting us to systematically compare the sets of genes occu-
pied by these histone modifications in each cell line with the set
occupied in all other lines (Figure 2; Supplemental Experimental
Procedures). We first performed all pairwise comparisons
among the ESC lines and found that 1.4% ± 0.8% of genes
had different H3K4me3 occupancy and 5.5% ± 2.0% of genes
had different H3K27me3 occupancy. Similarly, 0.7% ± 0.3%
genes varied for H3K4me3 and 6.0% ± 2.6% varied for
H3K27me3 among the iPSC lines. Pairwise comparison of ESC
and iPSC lines revealed that the variation for H3K4me3- (1.3% ±
0.7%) and H3K27me3- (6.0% ± 2.4%) occupied genes was not
significantly different from the variation observed within ESC
lines or within iPSC lines. In contrast, comparisons of the genes
enriched for H3K4me3 or H3K27me3 between pluripotent cells
(ESCs and iPSCs) and adult fibroblast cells revealed significantly
larger differences (12.3% ± 0.4% for H3K4me3; 67.8% ± 2.8%
for H3K27me3) (Figure 2; Table S2). Thus, we observed no
more variation between ESCs and iPSCs than was evident within
the ESC lines or within the iPSC lines. We also examined the
magnitude of the ChIP-Seq peaks associated with each gene
and again found that differences between ESCs and iPSCs
were no greater than the differences observed within ESC lines
and within iPSC lines (Table S2). These results suggest that theren iPSCs Share Key Features with ESCs
lue) and iPSCs (dashed blue). The transcription start site (TSS) and direction of
ene order was determined by highest average ChIP-Seq density in ESCs and
f genes is indicated by an arrow and the genomic region from –4.5kb to +4.5kb
K27me3 in ESCs (solid green) and iPSCs (dashed green). The TSS and direction
Gene order was determined by highest average ChIP-Seq density in ESCs and
f genes is indicated by an arrow and the genomic region from –4.5kb to +4.5kb
, and fibroblast cell lines. The position of the loci within chromosome 6 and the
C, and fibroblast cell lines. The position of the cluster within chromosome 7 and
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Figure 2. Similarity in Genes and Regions
Occupied by Modified Histones in ESCs
and iPSCs
(A) Pairwise comparisons of genes occupied by
H3K4me3 in ESCs, iPSCs, and fibroblast cells.
Each blue bar represents an individual pairwise
comparison of the set of genes identified as
enriched in one cell line with the set enriched in
a second cell line. Comparisons between two
ESC lines (ESC versus ESC), between two iPS
lines (iPSC versus iPSC), between an ESC line
and an iPSC line (ESC versus iPSC), and between
an ESC or iPSC line and fibroblast cells (ESC/iPSC
versus fibroblast) are shown in separate columns.
Gene occupancy was determined as described in
Supplemental Experimental Procedures.
(B) Pairwise comparisons of genes occupied by
H3K27me3 in ESCs, iPSCs, and fibroblast cells.
Each green bar represents an individual pairwise
comparison of the set of genes identified as en-
riched in one cell line with the set enriched in
a second cell line as in (A).
(C) Expression data for genes differentially occu-
pied by H3K4me3 in pluripotent cells (ESCs and
iPSCs) and fibroblast cells. Genes are ordered by
themagnitude of differential H3K4me3 occupancy
and relative gene expression is shown. Samples
with higher than average expression are shown
in red and samples with lower than average
expression are shown in green (scale in standard
deviations).
(D) Expression data for genes differentially occu-
pied by H3K27me3 in pluripotent cells (ESCs and
iPSCs) and fibroblast cells. Genes are ordered by
the magnitude of differential H3K27me3 occupancy and relative gene expression is shown. Samples with higher than average expression are shown in red
and samples with lower than average expression are shown in green (scale in standard deviations). See also Figure S1 and Tables S1–S4.
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pied by H3K4me3 or H3K27me3 between these human ESCs
and iPSCs.
We developed a statistical method (Supplemental Experi-
mental Procedures) to scan the entire genome and identify
regions with significant differential H3K4me3 and H3K27me3
occupancy between ESCs and iPSCs. To confirm the sensitivity
and specificity of this method, we compared all male ESC and
iPSC lines to all female ESC and iPSC lines and found a number
of regions with significant differences in histone modifications,
whichwere located almost exclusively on the sex chromosomes,
as expected (Table S3). We then compared female ESCs
to female iPSCs and found that iPSCs showed increased
H3K27me3 occupancy relative to ESCs at several X-linked
genes including Xist. We believe these differences in occupancy
are likely a consequence of exposing female iPSCs to high
oxygen conditions during derivation, since high oxygen growth
conditions induce X-inactivation in human pluripotent cells
(Lengner et al., 2010). To further validate our ability to detect
chromatin differences, we compared all pluripotent cells (ESCs
and iPSCs) to donor fibroblasts and observed a large number
of regions with differences in histone modifications (Table S3)
that were strongly associated with differences in gene expres-
sion (Figures 2C and 2D).
We then applied this method to identify statistically significant
differences in chromatin structure between ESCs and iPSCs and252 Cell Stem Cell 7, 249–257, August 6, 2010 ª2010 Elsevier Inc.found 50 genomic regions (29 genes) with differential H3K4me3
occupancy and four regions (two genes) with differential
H3K27me3 occupancy (Table S3). These regions of differential
occupancy represent a tiny fraction of the genome (0.003%),
and although there was no obvious theme associated with
them, we considered several possible causes for the differential
modification. First, we investigated whether these differences
were due to the presence of exogenous reprogramming factors
in iPSCs, but there were no significant differences in these chro-
matin modifications between transgene-containing and trans-
gene-excised iPSCs (Table S2; Soldner et al., 2009). Second,
we investigated whether the chromatin differences between
ESCs and iPSCs were due to residual epigenetic signatures
left from the parental fibroblast cell line, but found no evidence
that iPSCs contain H3K4me3 or H3K27me3 signatures that
reflect their cell of origin (Table S4). Lastly, we examined whether
any gene expression changes were associated with differences
in histone modification between ESCs and iPSCs, but found that
this was not the case (Figure S1). We conclude that there are
a small number of regions in these human ESCs and iPSCs
that show differences in H3K4me3- and H3K27me3-modified
nucleosomes. These differences involve a small fraction of the
genome and have little or no influence on gene expression.
However, we cannot exclude the possibility that these small
chromatin differences observed in undifferentiated cells may
exert subtle effects on cells upon differentiation.
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ESCs and iPSCs
Although the H3K4me3 and H3K27me3 profiles of the human
ESCs and iPSCs were nearly identical, we investigated the
possibility that there were differences in the gene expression
profiles between these ESCs and iPSCs. All 12 ESC and iPSC
lines, in addition to donor fibroblast cells, were subjected to
expression profiling and the data were analyzed with a single-
factor analysis of variance for testing statistical significance
with a Bayesian model of measurement error and a false
discovery rate correction for multiple hypothesis testing (Sharov
et al., 2005; Supplemental Experimental Procedures). We found
zero genes with statistically significant differential expression
between ESCs and iPSCs using this method. To gain greater
statistical power to identify small differences in transcript levels
between ESCs and iPSCs, we included expression data sets
from several additional ESC and iPSC lines that were not used
in the chromatin studies and repeated the analysis. In this panel
of 39 samples, we found only four genes with statistically signif-
icant differential expression between ESCs and iPSCs (Figures
3A and 3B; Table S5). These results are consistent with a study
that shows the overall mRNA andmicroRNA expression patterns
of isogenic mouse ESCs and iPSCs are nearly indistinguishable
within the exception of a few transcripts on chromosome 12qF1
(Stadtfeld et al., 2010).
Previous reports have observed that ESCs and iPSCs exhibit
considerable differences in gene expression (Chin et al., 2009;
Marchetto et al., 2009). To determine whether these gene
expression differences were consistently observed in multiple
laboratories, we re-examined a large collection of previously
published expression data comparing ESCs and iPSCs (Table
S5) (Maherali et al., 2008; Chin et al., 2009; Yu et al., 2009).
If there were truly consistent gene expression differences
between ESCs and iPSCs that were not a product of labora-
tory-specific biases in cell culture conditions, passage number,
RNA preparationmethods, or data processingmethods, it would
be expected that similar sets of genes would be identified
as differentially expressed in more than one of these studies.
However, we found that overlap between the genes identified
in each of these studies was extremely low (Figures 3B and 3D)
and conclude that there are very few, if any, consistent
differences in the gene expression programs of ESC and iPSC
lines. In contrast, the differential expression observed between
pluripotent (ESC and iPSC) lines and fibroblast lines was
highly reproducible across laboratories (Figures 3C and 3E;
Table S5).
Several studies have described a few hundred to several thou-
sand genes that show statistically significant differential expres-
sion between ESCs and iPSCs (Chin et al., 2009;Marchetto et al.,
2009;Ghosh et al., 2010). There are several possible reasons that
this result may have been obtained even if there is not, in reality,
a unique and consistent expression signature that distinguishes
iPSCs from ESCs. Cell culture conditions, derivation method,
passaging technique, reagents, amount of time in culture, micro-
array methods, and operator-specific microarray assay biases
can affect gene expression profiles. It is likely that uncontrolled
variables such as these contributed to the observation of differ-
ential gene expression between the ESC and iPSC samples,
given that we observe that ESC and iPSC expression data clusterby laboratory and not by ESC/iPSC identity (Figure 4). Our own
data indicate that differences in gene expression do exist
between various ESC and iPSC lines, but these differences do
not consistently distinguish iPSCs from ESCs.
DISCUSSION
ESCs and iPSCs have been shown to share key features of
pluripotency, including expression of pluripotencymarkers, tera-
toma formation, cell morphology, ability to differentiate into germ
layers, and tetraploid complementation (Okita et al., 2007;
Wernig et al., 2007; Boland et al., 2009; Kang et al., 2009; Smith
et al., 2009; Zhao et al., 2009; Stadtfeld et al., 2010). Human
iPSCs offer great promise for regenerative medicine and the
establishment of patient or subgroup-specific disease models,
but some reports suggest that ESCs and iPSCs may not be
equivalent (Chin et al., 2009; Marchetto et al., 2009; Ghosh
et al., 2010). We have mapped two histone modifications that
are critical for cell state and development in human ESCs and
iPSCs and find a very small number of consistent differences
between ESCs and iPSCs for these marks. These differences
in chromatin structure are not associated with differential gene
expression. Furthermore, the consistent differences between
ESCs and iPSCs are considerably smaller than the overall vari-
ability among these cell lines. In our analysis of gene expression
data across several studies, we find that variations in gene
expression occur among different ESC and iPSC lines, but we
do not observe a consistent signature that distinguishes iPSC
lines from ESC lines.
Previous studies comparing the gene expression profiles of
human ESCs and iPSCs argued that a recurrent gene expression
signature appears in iPSCs regardless of their origin or the
method bywhich theywere generated and suggested that iPSCs
should be considered a unique subtype of pluripotent cell (Chin
et al., 2009). This interpretation is inconsistent with our own. This
discrepancy is probably due to four features of the analytic
methods used by Chin et al. (2009) that, in our view, are key to
accurate data interpretation. First, a correction for multiple
hypothesis testing was not used, so the number of statistically
significant differentially expressed genes was greatly overesti-
mated. Second, there was not a requirement that gene expres-
sion change in the same direction. Third, the same ESC expres-
sion data was compared to both ‘‘early’’ and ‘‘late’’ passage
iPSCs, negating the assumption that these sets of differentially
expressed genes would be independent. Fourth, biases were
introduced into the identification of differentially expressed
genes that violate the assumption of independent assortment,
which is relied upon to calculate the statistical significance of
gene list overlaps. The use of a fold change threshold creates
a bias toward identifying genes with larger measurement error,
and collapsingmeasurements for several probe sets into a single
measurement for each gene could cause some genes to bemore
likely identified as differentially expressed across several data
sets. In studies that came to the conclusion that ESCs and iPSCs
have different gene expression signatures (Chin et al., 2009;
Marchetto et al., 2009; Ghosh et al., 2010), we believe uncon-
trolled laboratory-specific variables probably contributed to the
observation of differential gene expression. When we repeat
the analysis of published data with standard methods, we doCell Stem Cell 7, 249–257, August 6, 2010 ª2010 Elsevier Inc. 253
Figure 3. Limited Variation in Gene Expression between Human ESCs and iPSCs
(A) Unsupervised hierarchical clustering of whole genome expression data from ESCs (closed circle), iPSCs (open circle), and fibroblasts (hashed circle). Expres-
sion data was ordered by themagnitude of differential expression between pluripotent cells (ESCs or iPSCs) and fibroblast cells. Normalization and analysis for all
expression data is described in Supplemental Experimental Procedures.
(B) Differential gene expression between ESCs and iPSCs across multiple expression data sets. For each data set (top to bottom) the transcripts with
statistically significant differential expression between ESCs and iPSCs are shown. Within the set of differentially expressed transcripts from each data set,
expression data was ordered by the statistical significance of differential expression between ESCs and iPSCs and then aligned to all other data sets for compar-
ison. Samples with higher than average expression are shown in red and samples with lower than average expression are shown in green (scale in standard
deviations).
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Figure 4. Human ESC and iPSC Expression
Data Clusters More by Laboratory than by
ESC/iPSC Identity
Gene expression data sets for human ESCs,
iPSCs, and fibroblast cells from four laboratories
(Guenther et al., present study; Maherali et al.,
2008; Chin et al., 2009; Yu et al., 2009) were quan-
tile normalized as one group. Genes were Z score
normalized and data were subjected to hierar-
chical clustering (centered correlation distance,
centroid linkage) of samples. Genes were ordered
from greatest to least magnitude of differential
expression between pluripotent and fibroblast
cells. Solid circles indicate ESC samples, empty
circles indicate iPSC samples, and hashed circles
represent fibroblast cell samples. Data from indi-
vidual labs are coded by color as Guenther et al.
(blue), Maherali et al. (red), Chin et al. (purple),
and Yu et al. (green). See also Table S5.
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entially expressed between ESCs and iPSCs across several
laboratories (Figures 3B and 3D). Instead, we find that ESC
and iPSC expression data cluster more by laboratory than by
ESC/iPSC identity (Figure 4). Similarly, in mouse, most expres-
sion differences between ESCs and iPSCs are not consistently
observed across laboratories and are probably caused by
variations in genetic background or method of iPSC production
(Chin et al., 2009; Stadtfeld et al., 2010).
In summary, our experiments and analysis do not demonstrate
a significant difference between the H3K4me3 or H3K27me3
modifications or a consistent difference in the gene expression
programs of ESCs and iPSCs when examined after extended
culture. It is possible that there are small differences between
ESCs and iPSCs that we lacked the statistical power to observe
or that differences may occur in noncoding or regulatory RNAs.
Additionally, it is possible that there exist important epigenetic(C) Differential gene expression between fibroblasts and pluripotent cells (ESCs and iPSCs). Expression data w
ential expression between fibroblasts and ESCs/iPSCs in each data set and then aligned to all other data sets
expression are shown in red and samples with lower than average expression are shown in green (scale in s
(D) Overlap of differentially expressed genes between ESCs and iPSCs in various expression data sets. The n
ESCs and iPSCs are indicated in black. The total overlap of all gene sets is zero.
(E) Overlap of differentially expressed genes between fibroblast and pluripotent cells (ESCs and iPSCs) in va
differentially expressed between fibroblast and pluripotent cells are indicated in black. The total overlap of all
Table S5.
Cell Stem Cell 7, 249–25differences between ESCs and iPSCs
that are not reflected in the chromatin
marks that we examined, such as DNA
methylation events (Meissner et al.,
2008; Doi et al., 2009; Kim et al., 2010).
These possible changes in histone modi-
fication, DNAmethylation, or other epige-
netic marks may result in subtle func-
tional differences that could affect
differentiation or other cell processes
(Feng et al., 2010; Hu et al., 2010). Never-
theless, our results and the phenotypic
similarities shared by ESCs and iPSCs(Smith et al., 2009; Zhao et al., 2009) support the view that
ESC and iPSCs are nearly identical cell types.
EXPERIMENTAL PROCEDURES
Human ESC and iPSC Culture
All primary fibroblast cell lines described in this paper were purchased from the
Coriell Cell Repository (Camden, NJ). Fibroblasts were cultured in fibroblast
medium (Dulbecco’s modified Eagle’s medium [DMEM] supplemented with
15% fetal bovine serum [FBS; Hyclone], 1 mM glutamine [Invitrogen], 1% non-
essential amino acids [Invitrogen], and penicillin/streptomycin [Invitrogen]).
hiPSCs iPS A1, iPS C1, iPS4, and iPS A6 (Hockemeyer et al., 2008); hiPSCs
iPS PDB2lox-17 and iPS PDB2lox-21 (Soldner et al., 2009); hESC lines BG01 and
BG03 (National Institutes of Health code: BG01 and BG03; BresaGen, Inc.,
Athens, GA); and hESC cell lines WIBR1, WIBR2, WIBR3, and WIBR7 (White-
head Institute Center for Human Stem Cell Research) (Lengner et al., 2010)
were maintained on mitomycin C (MMC)-inactivated mouse embryonic fibro-
blast feeder layers in hESC medium (DMEM/F12 [Invitrogen] supplemented
with 15% FBS [Hyclone], 5% KnockOut Serum Replacement [Invitrogen],ere ordered by the statistical significance of differ-
for comparison. Samples with higher than average
tandard deviations).
umbers of genes differentially expressed between
rious expression data sets. The numbers of genes
gene sets is shown in white. See also Figure S2 and
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hESC and iPSC Chromatin and Gene Expression1 mM glutamine [Invitrogen], 1% nonessential amino acids [Invitrogen],
0.1 mM b-mercaptoethanol [Sigma], and 4 ng/ml FGF2 [R&D Systems]).
Cultures were passaged every 5 to 7 days either manually or enzymatically
with collagenase type IV (Invitrogen; 1.5 mg/ml).
ChIP-Seq
Detailed descriptions of antibodies, antibody specificity, ChIP, and ChIP-Seq
analysis methods used in this study have been published previously and
are provided in the Supplemental Experimental Procedures. The antibodies
for ChIP were specific for H3K4me3 (ab 8580; Abcam) and H3K27me3
(ab 6002; Abcam). Purified immunoprecipitated DNA was prepared for
sequencing according to a modified version of the Solexa Genomic DNA
protocol, applied to a flow-cell with the Solexa Cluster Station fluidics device,
and sequenced in accordance with Illumina’s standard protocols. Images
acquired from the Solexa sequencer were processed through the bundled
Solexa image extraction pipeline and aligned to the March 2006 build
(NCBI36.1/hg18) of the human genome with Bowtie software (Langmead
et al., 2009).
Expression Analysis
For RNA analysis, hESC and hiPSC colonies were mechanically isolated and
pooled for RNA extraction. Total RNA was isolated from ESCs, iPSCs, and
fibroblast cells with RNeasy MiniKit (QIAGEN). Five micrograms of total RNA
was labeled in accordance with standard Affymetrix protocols and hybridized
to Affymetrix HG-U133 2.0 plus arrays. The data were analyzed with Affymetrix
Gene Chip Operating Software using default settings. Expression data were
quantile normalized and analyzed for differential expression with the NIA Array
Analysis Tool (http://lgsun.grc.nia.nih.gov/ANOVA/). A more detailed descrip-
tion of the gene expression analysis methods is provided in the Supplemental
Experimental Procedures.
ACCESSION NUMBERS
Complete ChIP-Seq and gene expression data are available from the Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under accession
number GSE22499.
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Experimental Procedures and can be found with this article online at doi:10.
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